development and licensing

YORK: Aptamer Group plc (AIM: APTA), a developer of next-generation synthetic binders for the life science industry, announced Tuesday a new development and licensing agreement with an established global life sciences and diagnostics company, part of a major multinational conglomerate. Under the agreement, Aptamer will develop a custom Optimer®-Fc reagent for use in immunohistochemistry (IHC)…